Evidence map›Paper›PMID 41020902›Full record

ReviewCurrent issues in molecular biology2025

Natural Products Targeting the Androgen Receptor Signaling Pathway: Therapeutic Potential and Mechanisms.

Sitong Wu, Esveidy Isabel Oceguera Nava, Dennis Ashong, Guanglin Chen, Qiao-Hong Chen

Abstract readReview
In one paragraph

Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sitong WuDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.ORCID 0000-0002-7984-784X
Esveidy Isabel Oceguera NavaDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.ORCID 0000-0002-7215-7969
Dennis AshongDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.ORCID 0000-0002-8941-6023
Guanglin ChenDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.
Qiao-Hong ChenDepartment of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.ORCID 0000-0001-6753-1824

Funding

US Department of Commerce's Build Back Better Regional Challenge Grant Program N/A
6 · The paper itself

Abstract

The androgen receptor (AR) signaling pathway is the primary driver of prostate cancer initiation and progression, including the development of castration-resistant prostate cancer (CRPC). Because current AR-targeted therapies inevitably encounter drug resistance, novel strategies to suppress AR signaling are urgently needed. Natural products represent a rich and structurally diverse source of bioactive compounds capable of targeting AR at multiple regulatory levels. This review overviews the interactions between natural products and the AR signaling axis through distinct mechanisms, including inhibition of testosterone production and 5α-reductase activity, direct antagonism of AR, and induction of AR degradation. In addition, several compounds disrupt AR nuclear translocation, downregulate AR splice variants, or suppress AR signaling indirectly through epigenetic regulation, microRNA modulation, or interference with co-regulator networks. Preclinical studies provide compelling evidence that these agents can effectively interrupt AR signaling, thereby suppressing prostate cancer growth. However, challenges remain, particularly the limited pharmacokinetic characterization, lack of in vivo validation, and scarcity of clinical studies. Future research should focus on improving bioavailability, exploring synergistic combinations with existing therapies, and advancing well-designed in vivo and clinical investigations. Collectively, these efforts may establish natural products as lead compounds to modulate AR signaling for prostate cancer prevention and treatment.

Indexed as

androgen receptorantagonismdegradationnatural producttestosterone

Identifiers

PMID41020902
PMCPMC12468636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.